---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-011941"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:39:43.182285+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BeOne Medicines FY2025 revenue $5.34B (+40% YoY); guides FY2026 $6.2-6.4B

## Summary
- Total revenue $5.34B full year (+40% YoY); Q4 revenue $1.5B (+33% YoY).
- GAAP net income $286.9M vs loss $644.8M prior year; diluted EPS $2.53 vs loss $6.12.
- BRUKINSA global sales $3.9B (+49% YoY); Q4 sales $1.1B (+38%).
- Non-GAAP diluted EPS $8.09; Adjusted income from operations $1.1B from $45M prior year.
- FY2026 revenue guidance $6.2B-$6.4B; management cites pipeline strength and global leadership.

## SEC filing metadata
- accession: 0001628280-26-011941
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000162828026011941/0001628280-26-011941-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000162828026011941/bgne-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-011941
- JSON: https://secwatch.observer/filing/0001628280-26-011941.json
- Plain text: https://secwatch.observer/filing/0001628280-26-011941.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.